Advertisement
Mayo Clinic Proceedings Home
MCP Digital Health Home

Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway Variants

Published:December 20, 2022DOI:https://doi.org/10.1016/j.mayocp.2022.10.028

      Abstract

      Objective

      To study differences in cardiovascular risk factors and diseases between patients with and without genetic variants in the leptin-melanocortin pathway.

      Methods

      A cross-sectional study of patients with a history of severe obesity genotyped in June 2019 as participants of the Mayo Clinic Biobank was conducted in March 2022 to assess differences in cardiovascular risk and diseases between carriers of a heterozygous variant in the leptin-melanocortin pathway and noncarriers. Cardiovascular risk factors included hypertension, diabetes, dyslipidemia, and smoking. Cardiovascular disease includes coronary artery disease, peripheral artery disease, and cerebrovascular accidents. Patients with a history of bariatric surgery were excluded. We used logistic regression models to estimate the odds ratio and 95% CI, adjusting for age, body mass index (BMI), and sex.

      Results

      Among a total of 168 carriers (8%; 121 [72%] female; mean [SD] age, 65.1 [14.9] years; BMI, 44.0 [7.4] kg/m2) and 2039 noncarriers (92%; 1446 [71%] female; mean [SD] age, 64.9 [14.4] years; BMI, 42.9 [6.6] kg/m2), carriers had higher prevalence odds of hypertension (odds ratio, 3.26; 95% CI, 2.31 to 4.61; P<.001) and reported higher number of cardiovascular risk factors compared with noncarriers (2.4 [1.1] vs 2.0 [1.1]; P<.001). There were no significant differences in the adjusted odds associated with diabetes, dyslipidemia, smoking, or cardiovascular disease.

      Conclusion

      Despite having similar body weight and BMI, carriers of heterozygous variants in the leptin-melanocortin pathway had higher rates of hypertension than noncarriers. These findings point to an association between hypertension and leptin-melanocortin pathway variants.

      Abbreviations and Acronyms:

      BMI (body mass index), CVD (cardiovascular disease), MC4R (melanocortin 4 receptor), OR (odds ratio), POMC (proopiomelanocortin)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Heymsfield S.B.
        • Wadden T.A.
        Mechanisms, pathophysiology, and management of obesity.
        N Engl J Med. 2017; 376: 254-266
        • Abarca-Gómez L.
        • Abdeen Z.A.
        • Hamid Z.A.
        • et al.
        NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults.
        Lancet. 2017; 390: 2627-2642
        • Van Gaal L.F.
        • Mertens I.L.
        • De Block C.E.
        Mechanisms linking obesity with cardiovascular disease.
        Nature. 2006; 444: 875-880
        • Eckel R.H.
        • Kahn R.
        • Robertson R.M.
        • Rizza R.A.
        Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association.
        Circulation. 2006; 113: 2943-2946
        • Bray M.S.
        • Loos R.J.
        • McCaffery J.M.
        • et al.
        NIH working group report—using genomic information to guide weight management: from universal to precision treatment.
        Obesity (Silver Spring). 2016; 24 (Published correction appears in Obesity (Silver Spring). 2016;24(3):757): 14-22
        • Farooqi I.S.
        • O'Rahilly S.
        Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity.
        Nat Clin Pract Endocrinol Metab. 2008; 4: 569-577
        • van der Klaauw A.A.
        • Farooqi I.S.
        The hunger genes: pathways to obesity.
        Cell. 2015; 161: 119-132
        • Larsen L.H.
        • Echwald S.M.
        • Sørensen T.I.
        • Andersen T.
        • Wulff B.S.
        • Pedersen O.
        Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity.
        J Clin Endocrinol Metab. 2005; 90: 219-224
        • Schwartz M.W.
        • Woods S.C.
        • Porte D.
        • Seeley R.J.
        • Baskin D.G.
        Central nervous system control of food intake.
        Nature. 2000; 404: 661-671
        • Tallam L.S.
        • Stec D.E.
        • Willis M.A.
        • da Silva A.A.
        • Hall J.E.
        Melanocortin-4 receptor–deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia.
        Hypertension. 2005; 46: 326-332
        • Ni X.P.
        • Butler A.A.
        • Cone R.D.
        • Humphreys M.H.
        Central receptors mediating the cardiovascular actions of melanocyte stimulating hormones.
        J Hypertens. 2006; 24: 2239-2246
        • Olson J.E.
        • Ryu E.
        • Hathcock M.A.
        • et al.
        Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile.
        BMJ Open. 2019; 9e032707
        • Wiggins T.
        • Guidozzi N.
        • Welbourn R.
        • Ahmed A.R.
        • Markar S.R.
        Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis.
        PLoS Med. 2020; 17e1003206
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Sayk F.
        • Heutling D.
        • Dodt C.
        • et al.
        Sympathetic function in human carriers of melanocortin-4 receptor gene mutations.
        J Clin Endocrinol Metab. 2010; 95: 1998-2002
        • Greenfield J.R.
        • Miller J.W.
        • Keogh J.M.
        • et al.
        Modulation of blood pressure by central melanocortinergic pathways.
        N Engl J Med. 2009; 360: 44-52
        • Simonds S.E.
        • Pryor J.T.
        • Ravussin E.
        • et al.
        Leptin mediates the increase in blood pressure associated with obesity.
        Cell. 2014; 159: 1404-1416
        • Kuo J.J.
        • da Silva A.A.
        • Tallam L.S.
        • Hall J.E.
        Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation.
        Hypertension. 2004; 43: 370-375
        • Hall J.E.
        The kidney, hypertension, and obesity.
        Hypertension. 2003; 41 (pt 2): 625-633
        • Garrison R.J.
        • Kannel W.B.
        • Stokes III, J.
        • Castelli W.P.
        Incidence and precursors of hypertension in young adults: the Framingham Offspring Study.
        Prev Med. 1987; 16: 235-251
        • Burt V.L.
        • Cutler J.A.
        • Higgins M.
        • et al.
        Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991.
        Hypertension. 1995; 26 (Published correction appears in Hypertension. 1996;27(5):1192): 60-69
        • Hall J.E.
        • da Silva A.A.
        • do Carmo J.M.
        • et al.
        Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins.
        J Biol Chem. 2010; 285: 17271-17276
        • Bravo P.E.
        • Morse S.
        • Borne D.M.
        • Aguilar E.A.
        • Reisin E.
        Leptin and hypertension in obesity.
        Vasc Health Risk Manag. 2006; 2: 163-169
        • Sorof J.
        • Daniels S.
        Obesity hypertension in children: a problem of epidemic proportions.
        Hypertension. 2002; 40: 441-447
        • Abdullah A.
        • Stoelwinder J.
        • Shortreed S.
        • et al.
        The duration of obesity and the risk of type 2 diabetes.
        Public Health Nutr. 2011; 14: 119-126
        • Sakurai Y.
        • Teruya K.
        • Shimada N.
        • et al.
        Association between duration of obesity and risk of non-insulin-dependent diabetes mellitus: the Sotetsu Study.
        Am J Epidemiol. 1999; 149: 256-260
        • Wannamethee S.G.
        • Shaper A.G.
        Weight change and duration of overweight and obesity in the incidence of type 2 diabetes.
        Diabetes Care. 1999; 22: 1266-1272
        • Tanamas S.
        • Backholer K.
        • Wong E.
        • et al.
        Duration of obesity and incident hypertension in adults from the Framingham Heart Study.
        Int J Epidemiol. 2015; 44: i74-i75
        • Hall J.E.
        • Summers R.L.
        • Brands M.W.
        • Keen H.
        • Alonso-Galicia M.
        Resistance to metabolic actions of insulin and its role in hypertension.
        Am J Hypertens. 1994; 7: 772-778
        • Sasaki N.
        • Ozono R.
        • Higashi Y.
        • Maeda R.
        • Kihara Y.
        Association of insulin resistance, plasma glucose level, and serum insulin level with hypertension in a population with different stages of impaired glucose metabolism.
        J Am Heart Assoc. 2020; 9e015546
        • Fan W.
        • Dinulescu D.M.
        • Butler A.A.
        • Zhou J.
        • Marks D.L.
        • Cone R.D.
        The central melanocortin system can directly regulate serum insulin levels.
        Endocrinology. 2000; 141: 3072-3079
        • Lotta L.A.
        • Mokrosiński J.
        • de Oliveira E.M.
        • et al.
        Human gain-of-function MC4R variants show signaling bias and protect against obesity.
        Cell. 2019; 177 (e9): 597-607
        • Farooqi I.S.
        • Keogh J.M.
        • Yeo G.S.
        • Lank E.J.
        • Cheetham T.
        • O'Rahilly S.
        Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene.
        N Engl J Med. 2003; 348: 1085-1095
        • Bardia A.
        • Holtan S.G.
        • Slezak J.M.
        • Thompson W.G.
        Diagnosis of obesity by primary care physicians and impact on obesity management.
        Mayo Clin Proc. 2007; 82: 927-932
        • Mocarski M.
        • Tian Y.
        • Smolarz B.G.
        • McAna J.
        • Crawford A.
        Use of International Classification of Diseases, Ninth Revision codes for obesity: trends in the United States from an electronic health record–derived database.
        Popul Health Manag. 2018; 21: 222-230
        • Gupta P.P.
        • Fonarow G.C.
        • Horwich T.B.
        Obesity and the obesity paradox in heart failure.
        Can J Cardiol. 2015; 31: 195-202
        • Vashistha T.
        • Mehrotra R.
        • Park J.
        • et al.
        Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients.
        Am J Kidney Dis. 2014; 63: 612-622
        • Stovitz S.D.
        • Banack H.R.
        • Kaufman J.S.
        Structural bias in studies of cardiovascular disease: let's not be fooled by the “obesity paradox.
        Can J Cardiol. 2018; 34: 540-542
        • Yancy C.W.
        • Benjamin E.J.
        • Fabunmi R.P.
        • Bonow R.O.
        Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: executive summary.
        Circulation. 2005; 111: 1339-1349